Selecting ADHD Medications for New Patients

Initial Medication Selection

The American Academy of Pediatrics recommends starting with long-acting stimulant formulations, such as methylphenidate or amphetamine preparations, as first-line treatment, as they provide superior adherence, more consistent symptom control throughout the day, and lower risk of rebound effects compared to immediate-release formulations 1
Methylphenidate-based stimulants are the traditional starting point, with evidence showing 70% response rates when a full dose range is systematically trialed 2

Amphetamine-based stimulants should be considered if methylphenidate fails, as combined use of both classes yields >90% response rates when properly dosed 2
Long-acting formulations, such as extended-release, osmotic-release systems, or lisdexamfetamine, are strongly preferred over immediate-release preparations for better adherence and reduced abuse potential 3, 1

The American Academy of Child and Adolescent Psychiatry recommends beginning with low doses and titrating systematically to optimal effect, starting with 5 mg of methylphenidate or 2.5 mg of amphetamine/dextroamphetamine (immediate-release equivalent) 4
Titration should occur weekly in increments of 5-10 mg for methylphenidate or 2.5-5 mg for amphetamines until maximum benefit with tolerable side effects is achieved 4, 2

The maximum daily dose of methylphenidate should not exceed 60 mg (PDR limit), though expert consensus often limits to 40 mg daily or 25 mg single dose 4
The maximum daily dose of amphetamines should not exceed 40 mg 4

A structured 2-4 week titration phase with weekly dose adjustments based on systematic assessment is recommended, allowing rapid optimization as stimulant effects are seen immediately 2
Parent and teacher ratings should be collected at each dose level using standardized scales 4

Target symptoms, including core ADHD symptoms (inattention, hyperactivity, impulsivity), should be monitored 4
Side effects, such as insomnia, appetite suppression, headaches, social withdrawal, tics, and weight loss, should be systematically assessed at each visit 4
Vital signs, including blood pressure and pulse, should be monitored regularly 1

For preschool children (ages 4-5), behavior therapy should be tried first before considering medication, and methylphenidate should only be used if behavior therapy is insufficient, starting at lower doses with smaller increments 5
For adolescents, substance abuse should be screened for before initiating treatment, and abuse-deterrent formulations, such as lisdexamfetamine, dermal methylphenidate, or OROS methylphenidate, should be considered to reduce diversion risk 5
For adults with comorbid anxiety, anxiety does not contraindicate stimulants, and stimulants can indirectly reduce anxiety by improving executive function, but anxiety symptoms should be monitored carefully during titration 1

Atomoxetine requires 4-6 weeks for full effect, with a maximum daily dose of 100 mg, and is useful for comorbid anxiety 6
Extended-release guanfacine or clonidine can be used as monotherapy or adjunctive treatment, with an effect size of ~0.7 1

Underdosing is a common pitfall, and titration to optimal effect, not arbitrary dose limits, is recommended 2
Premature medication switching should be avoided, and a full dose range trial (including higher doses within safe limits) should be completed before declaring medication failure 2
Inadequate monitoring frequency, such as less than monthly visits during maintenance or less than weekly contact during titration, should be avoided 4
Ignoring teacher input, such as not obtaining teacher ratings, is a common pitfall, and school performance is a critical outcome measure 4
Weight-based dosing is not supported by evidence and should be avoided 2

Increase Strattera (atomoxetine) from 40 mg to 80-100 mg daily, as the current dose is at the starting level and far below the maximum recommended dose of 100 mg/day or 1.4 mg/kg/day, according to the American Academy of Child and Adolescent Psychiatry 7, 8
Titrate atomoxetine by 20 mg increments every 7-14 days to reach 60 mg, then 80 mg, and finally 100 mg if needed, based on evidence from the American Academy of Child and Adolescent Psychiatry 7, 8

Monitor cardiovascular parameters, including blood pressure and pulse, at each visit, as both stimulants and atomoxetine can increase these, as recommended by the American Heart Association 9
Monitor adverse effects, including appetite suppression, insomnia, headaches, gastrointestinal symptoms, and mood changes, as advised by the American Academy of Child and Adolescent Psychiatry 9

Switch to a longer-acting stimulant formulation, such as lisdexamfetamine (Vyvanse) 50-70 mg once daily, which provides 12-14 hours of coverage and has lower abuse potential, as recommended by the American Academy of Child and Adolescent Psychiatry 9

Consider switching to guanfacine extended-release or continuing atomoxetine monotherapy at optimized doses if cardiovascular concerns arise, as advised by the American Heart Association 9
Prefer lisdexamfetamine or atomoxetine due to lower abuse potential if substance abuse risk is present, as recommended by the Substance Abuse and Mental Health Services Administration 9